JUBLPHARMANSEJubilant Pharmova LimitedHighNeutral
Announced Fri, 22 May · 14:51 IST

Jubilant Pharmova Limited has informed the Exchange regarding Appointment of Mr. Ashish Mukkirwar as Chief Financial Officer of the company w.e.f. May 23, 2026.

Cfo ResignedKmp ResignedManagement Changes View source PDF

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹1011.00
prior close
₹1007.55
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.4-0.0-0.3-1.1-2.1-2.1-1.8-3.4-3.2-2.0-5.5-2.1
Up moveDown movePending
AI summary

Jubilant Pharmova's CFO Mr. Arun Kumar Sharma stepped down effective close of business on May 22, 2026, after his tenure, and has transitioned to the new role of Advisor to the Chairmen. The Board simultaneously approved the appointment of Mr. Ashish Mukkirwar as the new CFO and Key Managerial Personnel (KMP) effective May 23, 2026. Mukkirwar brings over 20 years of experience, having previously served as Group VP & CFO – Global Formulations Business at Glenmark Pharmaceuticals, and held senior roles at Moelis & Company and UBS Investment Banking. He holds an MBA from IIM Kolkata. The changes were approved based on recommendations from the Nomination, Remuneration and Compensation Committee and the Audit Committee.

Likely market impact

The appointment of an experienced external CFO with a strong M&A and investor relations background could be viewed positively by the market, especially given the smooth internal transition where the outgoing CFO remains as an advisor.